Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add ...

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia …

The poster will be made available on the Presentations & Research page of Unicycive’s website following the poster ...
Renal & Urology News

Phosphate, Parathyroid Hormone Levels at Dialysis Session Start Vary by Time of Day

Serum levels of phosphate and parathyroid hormone are lower early in the day and higher late in the day, recently reported data suggest. Phosphate and parathyroid hormone (PTH) levels at the start of ...
ascopubs.org

Efficacy and Safety of Oral Fludarabine Phosphate in Previously Untreated Patients With Chronic Lymphocytic Leukemia

18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer Eighty-one patients received treatment. According to International Workshop on Chronic ...